Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma

Open access
Liao, Rachel G., Jung, Joonil, Tchaicha, Jeremy, Wilkerson, Matthew D., Sivachenko, Andrey, Beauchamp, Ellen M., Liu, Qingsong, Pugh, Trevor J., Pedamallu, Chandra Sekhar, Hayes, D. Neil, Gray, Nathanael S., Getz, Gad, Wong, Kwok-Kin, Haddad, Robert I., Meyerson, Matthew, Hammerman, Peter S.·2013·Cancer Research

Abstract

A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung SCC) has recently been reported, enabling the identification of genomic events that contribute to the oncogenesis of this disease. In lung SCC, one of the most frequently altered receptor tyrosine kinase families is the fibroblast growth factor receptor (FGFR) family, with amplification or mutation observed in all four family members. Here, we describe the oncogenic nature of mutations observed in FGFR2 and FGFR3, each of which are observed in 3% of samples, for a mutation rate of 6% across both genes. Using cell culture and xenograft models, we show that several of these mutations drive cellular transformation. Transformation can be reversed by small-molecule FGFR inhibitors currently being developed for clinical use. We also show that mutations in the extracellular domains of FGFR2 lead to constitutive FGFR dimerization. In addition, we report a patient with an FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib. These findings provide new insights into driving oncogenic events in a subset of lung squamous cancers, and recommend future clinical studies with FGFR inhibitors in patients with lung and head and neck SCC. Cancer Res; 73(16); 5195–205. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-3950

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 167

Metadata

Authors
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., Gray, N. S., Getz, G., Wong, K.-K., Haddad, R. I., Meyerson, M., & Hammerman, P. S.
Venue
Cancer Research
Published
2013-08-13
Volume
73
Issue
16
Pages
5195-5205
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2136549416
Cited by
167
References
9
FWCI
12.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-3950
The paper
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., Gray, N. S., Getz, G., Wong, K.-K., Haddad, R. I., Meyerson, M., & Hammerman, P. S. (2013). Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-3950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.